Title: Yoga Effect on Quality-of-Life Study Among Patients with Idiopathic Pulmonary

Fibrosis (YES-IPF)

Authors and affiliation: Suha Kadura[1], Soumik Purkayastha[2,6], Josh Benditt[1], Amit Anand[3],

Bridget Collins[1], Miguele De Quadros[4], Mafara Hobson[4], MJ Biswas[4], Lawrence Ho[1], Cathie

Spino[5], Ganesh Raghu*[1]

1- Division of Pulmonary, Critical Care and Sleep Medicine, Center for Interstitial Lung

Diseases, Department of Medicine, University of Washington, Seattle, WA, USA

2- Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.

3- Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical

Center, Boston, MA, USA.

4- Independent certified yoga instructors

5- Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

6- Center for Health Equity Research and Promotion, Pittsburgh, PA, USA

***Corresponding Author:** Ganesh Raghu, MD**,** University of Washington, Campus Box

356175, Seattle, WA 98195 USA**.** Email: graghu@uw.edu

Running title: Yoga Effect on Quality-of-Life in IPF Patients;

Descriptor Number: 9.23 Interstitial Lung Disease;

Total words: 3337

Abstract words: 247

Summary: We examine if the implementation of a modified yoga program improves patient-

reported outcomes in patients with idiopathic pulmonary fibrosis. Our study reveals

significant post-yoga improvements in the yoga group compared to the control group across

different patient-reported outcomes. Such outcomes are meaningful endpoints in patients

with idiopathic pulmonary fibrosis and serve as a critical endpoint in related clinical trials.

Contributions:

1. *Suha Kadura:* Data gathering, interpretation of result, writing first draft, revised

versions and collated inputs from all authors of the manuscript.

2. *Soumik Purkayastha:* Data analyses, interpretation of result, writing first draft, revised

versions and collated inputs from all authors of the manuscript.

3. Josh Benditt and Amit Anand: Developed the protocol and study design for the

modified yoga program /exercises used in the trial; reviewed the data analyzed,

interpreted results.

4. Josh Benditt, Amit Anand, Miguele De Quadros, Mafara Hobson, and MJ Biswas:

Certified yoga instructors for patients.

5. Bridget Collins: Enrolled consenting participants in the study, participated in study

design, interpretation of results, reviewing manuscript and provided input.

6. *Lawrence Ho:* Enrolled and encouraged patients to participate in the trial.

7. *Cathie Spino:* Reviewed data analyses and interpretation, reviewed manuscript and

provided input.

8. *Ganesh Raghu:* designed the trial and study protocol, enrolled consenting

participants in the study, interpretation of results, supervised the conduct of trial and

execution of the trial; manuscript writing.

All authors reviewed the drafts of manuscript, provided input, contributed to writing the

manuscript and approved the final manuscript for submission.

Data availability statement: In accordance with our protocol registered at ClinicalTrials.gov (NCT02848625), individual participant data from this study will not be made available publicly. This approach was established to protect participant privacy and confidentiality as stated in our informed consent process. Summary data supporting the findings of this study are available within the article and its supplementary materials. Researchers interested in collaborative analyses may contact the corresponding author with specific research questions and proposed methodologies for consideration.

Funding Statement: No external funding or financial support was received for the conduct of this research, data analysis, manuscript preparation, or submission.

56   **ABSTRACT**

Rationale: Patients with idiopathic pulmonary fibrosis have poor health-related quality of

life.

Objective: Determine whether a modified yoga program in patients with idiopathic

pulmonary fibrosis improves quality of life compared to usual care.

Methods: Randomized controlled, non-blinded, pilot clinical trial lasting 12 weeks with 2

arms involving 63 adults with idiopathic pulmonary fibrosis. The yoga program-arm

consisted of interventions such as seated postures, breathing and meditation exercises

designed by authors for idiopathic pulmonary fibrosis patients. The control arm continued

with usual standard of care. Analysis of covariance was performed; no multiplicity

adjustments were made on account of this being a pilot study.

Measurements: The primary outcomes were week-12 scores in seven patient-reported

instruments, each with sub-domains, totaling 21 outcomes.

Results: 60 of the 63 participants (32 randomized to yoga; 31 receiving standard of care)

completed the study (one death in each arm and one withdrawal in yoga group). Analysis of

covariance for week-12 scores, adjusting for baseline scores and confounders, revealed

significant treatment effects favoring yoga in the L-IPF cough domain (-9.29 points, 95% CI -

18.37 to -0.20; p=0.045), in the L-IPF total score (-7.11, 95% CI -13.15 to -1.06; p=0.022), and

in the R-scale-PF cough domain (-1.18, 95% CI -2.27 to -0.10; p=0.034) in the study

population.

Conclusion: Patients with idiopathic pulmonary fibrosis participating in a yoga program

demonstrated significant improvement in quality of life assessed by the cough and total

scores of L-IPF and the cough score of R-scale-PF than those receiving usual care.

Abstract word count: 247

Key words: Idiopathic Pulmonary Fibrosis, Yoga, Health-Related Quality-of-Life, Patient-

Reported Outcome Measures, Cough.

 TEXT

1. Introduction

Idiopathic pulmonary fibrosis carries significant mortality and symptom burden, with limited

therapeutic options. Despite the discovery of antifibrotic agents that slow the rate of decline

of forced vital capacity, patients living with idiopathic pulmonary fibrosis suffer from

persistent respiratory symptoms and diminished quality of life. There are no available

pharmacologic therapies for idiopathic pulmonary fibrosis that have been shown to impact

patient-reported outcomes, such as symptoms or health-related quality-of-life. Though

biomarkers such as forced vital capacity or image patterns may identify effects of

interventions on biological pathways of the disease process, they likely do not fully

encompass treatment impact on how patients 'feel, function, and survive,' and only weakly

correlate with patient-reported symptom measures [2–4]. In this context, identification of

treatment strategies for idiopathic pulmonary fibrosis with the aim of enhancing patients'

quality of life is a top priority.

Yoga is a mind-body practice that has become an increasingly popular and effective method

to treat and manage symptoms of chronic diseases, and is the most commonly used

complementary health approach in the United States [5]. According to a 2017 national survey,

about one in seven U.S. adults practiced yoga in the past 12 months, and the percentage of

people practicing yoga grew from 2007 to 2017 [6]. A mounting body of literature demonstrates

the benefits of yoga not only in components of general wellness including stress,

mental/emotional health, and sleep quality, but has also been shown to improve symptoms

and quality of life in various chronic diseases including Chronic Obstructive Pulmonary

Disease, asthma, cancer, heart failure, arthritis, and chronic pain [7-12].

Although classical yoga includes other elements, yoga as commonly practiced in the United

States typically emphasizes standard components such as breathing exercises

(pranayama), postures (asanas), and meditation (dhyana). Central to asanas and

pranayama is diaphragmatic breathing, which may lead to improved chest expansion and

decreased work of breathing. Studies evaluating the benefits of yoga in chronic respiratory

diseases (largely asthma and Chronic Obstructive Pulmonary Disease) have shown

improvement in variables such as forced expiratory volume in 1 second, tidal volume and

minute ventilation, as well as increase in measures such as alveolar gas exchange and

improved submaximal and maximal oxygen consumption, in addition to quality of life [13-16].

We sought to assess the effect of a standardized virtual, modified yoga program (henceforth,

treatment) designed specifically for individuals with idiopathic pulmonary fibrosis at our

center, with the effect on health-related quality of life as a primary objective. We

hypothesized that a 12-week modified yoga program, designed specifically for individuals

with idiopathic pulmonary fibrosis, would improve health-related quality of life compared to

usual care, with effects potentially most pronounced for symptoms like cough and dyspnea

that might benefit from improved breathing techniques.

2. Methods

2.1 Study design: This study was a non-blinded, single center, randomized pilot trial

conducted by the Center for Interstitial Lung Diseases at the University of Washington

Medical Center. It was approved by the Institutional Review Board at the University of

Washington and registered with ClinicalTrials.gov (NCT02848625). The trial protocol,

including detailed statistical analysis plan appears in Sections 2 to 6 of Online Data

Supplement.

2.2 Participants: Consenting adults with idiopathic pulmonary fibrosis meeting criteria

established in 2018 by the American Thoracic Society, European Respiratory Society,

Japanese Respiratory Society, and Latin American Thoracic Society at time of screening were

eligible [17]. Exclusion criteria included comorbidities interfering with yoga (e.g.,

musculoskeletal discomfort), evaluation for lung transplant or hospice care, participation in

yoga and/or pulmonary rehabilitation outside of the study at screening and during the study

period. All patients were otherwise allowed to receive usual care for idiopathic pulmonary

fibrosis including treatment with *nintedanib* or *pirfenidone* and supplemental oxygen when

necessary, during the study period.

2.3 Randomization and masking: Eligible participants were randomly allocated in a 1:1

ratio to either the treatment arm (following the modified yoga program), or the control arm

(receiving standard of care and following usual activities) with stratification by supplemental

oxygen need prior to enrollment to account for disease severity. The randomization schedule

was prepared using computer-generated permuted random blocks of size 4 for each

stratum. The sequence of allocation was hidden from the investigators to prevent selection

bias. Participants, investigators, and providers were not blinded to intervention. See Figure

E1 of the Online Data Supplement for details on the study protocol.

2.4 Procedures: The modified yoga program consisted of seated postures, breathing, and

meditation exercises designed by 5 certified yoga instructors tailored for fibrosis patients

(see Table E1 and Section 9 of Online Data Supplement). Chair yoga, as used in our study, is

a gentler yoga alternative for older adults. Classical yoga with more strenuous movement

that may involve poses on the floor, significant joint and muscle stretching was considered

not to be appropriate for the typical idiopathic pulmonary fibrosis patient population. Chair

yoga is quite popular and many studios and training courses for its practice are available,

with prior studies demonstrating benefit in elderly patients [18].

The protocol was intended to be in-person, though was amended due to the COVID-19

pandemic to reduce exposure risk, with participants randomized to the treatment arm

participating in group sessions conducted virtually via Zoom in individuals' homes (5-6 per

group). Sessions lasted one hour, twice/week, for 12 consecutive weeks, led by a certified

yoga instructor. The same instructor led each group's sessions. Participants received a

secure link to a pre-recorded demo video to practice during their free time (see Section 4 of

Online Data Supplement).

Participants in the treatment group received a journal at the beginning of the program and

were encouraged to write in it at the end of each class (see Section 8 of Online Data

Supplement). Journal entries were used in the qualitative assessment of the program.

Attention control conditions were not implemented for the control group due to lack of

feasibility and resource limitations during the pandemic. All patients were evaluated in

person at baseline and after 12 weeks when lung function and 6-minute walk tests were

performed, and patient-reported outcome measurements were collected.

2.5 Outcomes: The *primary outcomes* measured were total/domain-specific scores from

seven validated health-related quality of life tools collected at baseline and at the end of the

12-week study period. These included the Living with Idiopathic Pulmonary Fibrosis

symptoms module (L-IPF symptoms), a recently developed and validated visual analog

scale (VAS) for IPF called Raghu scale for pulmonary fibrosis (R-Scale-PF), King's Brief

Interstitial Lung Disease questionnaire (K-BILD), EuroQol-Five-Dimensional Five-Level

questionnaire (EQ-5D-5L), Hospital Anxiety and Depression (HAD) Scale, Patient-Reported

Outcomes Measurement Information System Sleep Disturbance and Sleep-Related

Impairment (PROMIS SD and SRI), and Epworth Sleepiness Scale (ESS) [19–26].

Secondary outcomes included changes from baseline to 12 weeks in absolute and percent

predicted forced vital capacity (FVC), diffusing capacity of the lungs for carbon monoxide

(DLCO), and 6-minute walk distance (6MWD).

2.6 Questionnaires for Patient Reported Outcomes

L-IPF questionnaire symptoms module: The L-IPF symptoms module contains 15 items, with the total score derived as the average of the dyspnea (7 items), cough (5 items), and energy/fatigue (3 items) domains, each with a 24-hour recall period [19]. Each item is rated on a 5-point scale (0-4), with higher scores connoting greater impairment. The minimum clinically important difference estimates have been reported as 6 to 7 for the dyspnea domain score and 4 to 5 points for the cough domain score, though these estimates were investigated in a population of patients with progressive interstitial lung disease, other than idiopathic pulmonary fibrosis, which does not specifically apply to our study population [27].

R-scale-PF questionnaire: The R-scale-PF is a visual analog scale assessing 5 domains (cough, shortness of breath, fatigue, depressed mood, and overall sense of well-being). Each domain score ranges from 0 to 10 with 0.5 increments. The total score ranges from 0 to 50 with lower numbers indicating better health-related quality of life [20]. A minimum clinically important difference estimate has not yet been defined in fibrosis patients.

Details for the remaining utilized questionnaires including K-BILD, EQ-5D-5L, HADS, PROMIS SD and SRI, and ESS are provided in Section 7 of Online Data Supplement.

2.7 Statistical analysis

Study Design and Analysis Population: This pilot trial utilized patient-reported outcomes as primary outcomes, with sample size determined by feasibility rather than power

calculations, as well-defined data on clinically important differences were not available for

the fibrosis population in the implemented instruments. The primary analysis set was the

modified intention-to-treat population defined as all randomized participants with a week

12 visit

Primary Analysis: Between-group comparisons for outcome scores were conducted using

analysis of covariance (ANCOVA), adjusting for baseline questionnaire scores, age, sex, BMI,

and supplementary oxygen use. Any of the outcomes that demonstrated significant

improvement in the study population was considered a favorable outcome. All analyses

were conducted in R (version 4.4.1). Given this is a pilot trial, p-values were not adjusted for

multiple comparisons.

Missing data were handled via multiple imputation with chained equations. Sensitivity

analyses using complete cases were performed. For more information on missing data

handling as well as sensitivity analyses see Section 6 of Online Data Supplement.

3. Results

Between January 1-June 10, 2021, 63 consecutive, eligible patients provided consent. Thirty-

two were randomly assigned to yoga and 31 to the control group. Thirty (94%) of 32

participants in the yoga group and 30 (97%) of 31 participants in the control group completed

12 weeks of assessment (Figure 1) to form the study population. One participant from each

study arm was missing at least one week 12 questionnaires. DLCO data were not available

for one participant at baseline and four at week 12, one did not have week 12 FVC data, and

two participants were missing 6MWD at baseline and 4 at week 12.

Baseline demographics are presented in Table 1. Most participants were male (41 [68%] of

60), with mean age of 73.4 [SD 8.21] years. Median disease duration was 3.2 years. Most

characteristics are comparable between the treatment groups, with no clinically meaningful

differences. Participants had mild to moderate impairment in lung function at baseline

(mean FVC% predicted was 74.8 [SD 21.44] and % predicted DLCO was 54.0 [18.27]).

Twenty-two (37%) participants used supplemental oxygen. Fifty-one (85%) participants were

on background antifibrotic therapy with either *nintedanib* or *pirfenidone*. Comorbid

conditions included obstructive sleep apnea in 28 (47%) participants, emphysema in 5 (8%),

gastroesophageal reflux disease (confirmed by pH probe) in 25 (42%), and pulmonary

hypertension (confirmed by right heart catheterization) in 11 (18%).

In Table 2, adjusted comparisons between yoga and control groups for primary outcomes

using multiple imputation are reported. For the L-IPF cough domain, the yoga group showed

improvement from baseline score (mean 27.83 [SD = 25.69]) to week 12 (mean 18.10

[21.23]), while the control group remained stable (baseline: 24.83 [22.95]; week 12: 25.00

[22.09]). The imputation-based analysis showed a treatment effect that was borderline

statistically significant, favoring yoga (adjusted treatment effect: -9.29; 95% CI: [-18.37, -

0.20]; p=0.045). The yoga group showed improvement from baseline total L-IPF score (mean

30.84 [SD = 18.77]) to week 12 (mean 23.37 [16.49]), while the control group remained stable

(baseline: 26.49 [19.60]; week 12: 27.16 [19.92]). The imputation-based analysis showed a

treatment effect that was statistically significant, favoring yoga (adjusted treatment effect: -

7.11; 95% CI: [-13.15, -1.06]; p=0.022). In the R-scale-PF cough domain, the yoga group

demonstrated substantial reduction in cough (baseline: 3.20 [SD 2.64]; week 12: 2.07

[2.31]), whereas the control group showed a slight worsening (baseline: 2.87 [2.21]; week 12:

3.14 [2.56]). The imputation-based analyses demonstrated significant treatment effects (-

1.18; 95% CI: [-2.27, -0.10]; p=0.034). Figure E3 of Online Data Supplement graphically

depicts the distribution of cough domain scores via L-IPF, L-IPF total scores, and cough

domain scores via R-Scale-PF at baseline and week 12, shown separately for control and

treatment groups using violin plots with individual patient data points.

Figure 2 illustrates individual patient trajectories from baseline to week 12 for cough domain

scores measured by L-IPF and R-Scale-PF questionnaires as well as L-IPF total score by

study arm, with average changes indicated by solid black lines.

In Table E2 of Online Data Supplement, unadjusted and adjusted comparison between the

yoga and control groups for secondary outcomes are shown using the multiple imputation

approach. There were no significant differences in any of the secondary outcomes over 12

weeks.

Since the findings from the sensitivity analyses using complete cases were consistent with

those of the primary analyses, detailed results are presented in Table E3 of Online Data

Supplement. While not all p-values reflect statistical significance, the directionality of

treatment effects for all primary outcomes was consistent, with the yoga group generally

showing improvement and the control group showing either stability or slight worsening of

scores.

There were no adverse effects related to yoga treatment. Attendance and participation in the

yoga group was satisfactory, with 100% attendance by 21 of 30 participants at all 24

sessions. Apart from one participant missing 5 sessions due to an unanticipated personal

matter, 8 other participants without full attendance did not miss more than 2 sessions

throughout the program.

A qualitative content analysis was performed through participants' journals. Central themes

identified leading to sense of improvement in overall well-being included social connection,

managing fibrosis symptoms, changed mindset (Figure E2 of Online Data Supplement).

Regarding social connection, participants reported feeling a sense of community and

support during the program. Participants felt less self-conscious about experiencing

symptoms (such as cough) and enjoyed speaking with others about their experiences and

being able to monitor their progress alongside others who shared their diagnosis. Several

participants reported incorporating more deliberate and controlled breathing techniques

into daily activities, with improved knowledge and understanding of the connection between

mind and body. From a mindset standpoint, participants reported feeling an increase in

confidence in their ability and motivation to increase physical activity and push themselves

despite their debilitating diagnosis.

4. Discussion

This pilot trial provides evidence that participants receiving 12-week modified yoga program

experienced improvements in health-related quality-of-life outcomes, particularly in the

cough domain scores of both the L-IPF and R-Scale-PF questionnaires, compared to those

who continued usual daily activities. The strength of this conclusion is bolstered by

consistency of results showing greater improvements in multiple quality of life

instruments—including HADS, K-BILD, total R-scale-PF score, PROMIS SRI and ESS,

following intervention in the yoga group than the control group.

To our knowledge, this is the first idiopathic pulmonary fibrosis clinical trial reporting

improvement in outcomes in the intervention group as primary endpoints. As emphasized

by a recent landmark international symposium involving patients, academic investigators,

and regulatory representatives, endpoints in idiopathic pulmonary fibrosis clinical trials

should resonate more closely with the tangible patient experience [2]. The integration of

adequately validated outcomes is an important step in this direction. The statistically

significant improvement in the L-IPF cough domain score (and numeric improvement in

KBILD score) in the yoga arm participants in our study is clinically meaningful to patients, as

both of these questionnaires were developed with input from idiopathic pulmonary fibrosis

patients and have undergone extensive validity and reliability testing [2,21,28]. In a patient

population with progressive interstitial lung disease, other than idiopathic pulmonary

fibrosis, Swigris et al. provided estimates of 4 to 5 points in the L-PF cough domain score as

a clinically meaningful threshold [27]. Although our study population included patients with

fibrosis only, the observed change in the L-IPF cough domain exceeded this threshold. The

inclusion of the recently developed R-Scale-PF as a health-related quality-of-life measure in

our study is aligned with evolving research in idiopathic pulmonary fibrosis aimed at

adopting psychometric tools such visual analogue scales that can be used to rapidly assess

the severity of symptoms and other traits in patients with idiopathic pulmonary fibrosis, in

both research and clinical settings [20,29–31]. Other scale tools, such as cough visual analogue

scale, carry prognostic and quality of life value in fibrosis and are being increasingly used in

interventional trials in idiopathic pulmonary fibrosis [32,33].

Previous studies have demonstrated a clear benefit of yoga in other chronic respiratory

diseases on validated health-related quality-of-life scores, including asthma and COPD

[8,9,34,35]. Our study is the first to evaluate the effect of yoga on patients with idiopathic

pulmonary fibrosis with positive findings despite the barrier of virtual rather than in-person

sessions due to the COVID-19 pandemic, particularly since previous data suggests

participant preference for in-person yoga classes [36]. Two unpublished results showed mixed

results regarding improvements in quality of life scores following participation in yoga,

although both were designed as feasibility/safety studies with less than 20 participants each

(one study in idiopathic pulmonary fibrosis patients and another in patients with fibrotic ILD

of any cause) [37,38]. We did not find statistically significant improvement in anxiety and

depression scores measured by the HADS in contrast to a previous study that evaluated a

general group of chronic lung disease patients awaiting lung transplant [39].

Although numerically greater improvements in the ESS and PROMIS SRI scores were

observed in the yoga group, our study did not show statistically significant benefit in sleep

quality despite prior reports showing improvement in sleep quality and insomnia with yoga

participation in other patient populations [40]. There is a complicated relationship with sleep

quality in idiopathic pulmonary fibrosis patients, in whom comorbid sleep related breathing

disorders such as OSA and insomnia are common and likely worsen the quality of life and

may even increase mortality in patients with idiopathic pulmonary fibrosis [41–43]. Another

factor reported to be potentially contributing to increased arousal index in idiopathic

pulmonary fibrosis is comorbid gastroesophageal reflux disease [41]. Further prospective

studies are needed to better evaluate the effects of yoga on overall sleep quality in idiopathic

pulmonary fibrosis patients.

Possibilities of the potential mechanism for improved quality of life in fibrosis patients

participating in yoga include improved posture, allowing more efficient use of abdominal and

diaphragmatic muscles. Implementation of pranayama practice optimizes breath control

and synchronization of movements with breath, which likely helps to manage symptoms of

breathlessness. Various yoga exercises such as deep diaphragmatic breathing can improve

vagal tone, which may help diminish enhanced cough reflex sensitivity as previously

described in patients with idiopathic pulmonary fibrosis [44].

The results of this study must be interpreted in the context of several limitations amidst its

strengths. First, this was a single center, pilot trial designed to assess feasibility with the aim

of informing future studies with adequate sample size calculations and powered to detect

significant differences in trial outcomes between groups. This was an exploratory pilot trial

designed primarily to assess feasibility and generate hypotheses for future studies. We

acknowledge that with multiple endpoints (21 in total) and no adjustment for multiple

comparisons, our findings are vulnerable to Type I error. However, the consistency of findings

across multiple cough-related measures strengthens our confidence in these specific

results. Future confirmatory trials should pre-specify primary endpoints and include

appropriate statistical adjustments. A second limitation is the relatively small sample size

and study duration of only 12 weeks. Third, since a blinded trial is not possible, it is difficult

to distinguish between yoga-specific and nonspecific benefits (e.g. expectation bias, social

connection during class, interpersonal skills of the yoga instructor). Finally, future trials

should include well-validated measures of cough such as The Leicester Cough

Questionnaire [45,46].

In summary, this is the first idiopathic pulmonary fibrosis clinical trial demonstrating

improvement in patient-reported outcomes as primary endpoints, and the first study to

evaluate the effect of yoga practice in this patient population. Besides demonstrating safety

and feasibility of a yoga program that patients can engage in from the comfort of their homes,

the study demonstrated improved health-related quality of life measures in patients with

idiopathic pulmonary fibrosis following participation in a yoga program supervised by

instructors. These results are clinically significant given the critical need for therapeutic

options that improve outcomes that are meaningful to patients suffering with this disease.

A larger, multi-center trial is warranted to further establish improved health-related quality

of life via participation in a yoga program tailored for patients with idiopathic pulmonary

fibrosis, in keeping with an emphasis on patient-centered outcomes.

REFERENCES

1. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and

Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice

Guideline. *Am J Respir Crit Care Med*. 2022;205(9):e18-e47. doi:10.1164/rccm.202202-

0399ST

2. Raghu G, Ghazipura M, Fleming TR, et al. Meaningful Endpoints for Idiopathic

Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'.

Report of a Collaborative Discussion in a Symposium with Direct Engagement from

Representatives of Patients, Investigators, the National Institutes of Health, a Patient

Advocacy Organization, and a Regulatory Agency. *Am J Respir Crit Care Med*.

2024;209(6):647-669. doi:10.1164/rccm.202312-2213SO

3. Swigris JJ, Han M, Vij R, et al. The UCSD shortness of breath questionnaire has

longitudinal construct validity in idiopathic pulmonary fibrosis. *Respir Med*.

2012;106(10):1447-1455. doi:10.1016/j.rmed.2012.06.018

4. Aronson KI, Martin-Schwarze AM, Swigris JJ, et al. Validity and Reliability of the Fatigue

Severity Scale in a Real-World Interstitial Lung Disease Cohort. *Am J Respir Crit Care

Med*. 2023;208(2):188-195. doi:10.1164/rccm.202208-1504OC

5. *2016 Yoga in America Study Conducted by Yoga Journal & Yoga Alliance*.

https://www.yogaalliance.org/2016YogaInAmericaStudy

6. Clarke TC, Barnes PM, Black LI, Stussman BJ, Nahin RL. Use of Yoga, Meditation, and

Chiropractors Among U.S. Adults Aged 18 and Over. *NCHS Data Brief*. 2018;(325):1-8.

7. Selvan P, Hriso C, Mitchell J, Newberg A. Systematic review of yoga for symptom

management during conventional treatment of breast cancer patients. *Complement*

Ther Clin Pract. 2022;48:101581. doi:10.1016/j.ctcp.2022.101581

8. Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for chronic obstructive

pulmonary disease. Cochrane Airways Group, ed. *Cochrane Database of Systematic*

Reviews. Published online October 17, 2012. doi:10.1002/14651858.CD008250.pub2

9. Yang ZY, Zhong HB, Mao C, et al. Yoga for asthma. *Cochrane Database Syst Rev*.

2016;4(4):CD010346. doi:10.1002/14651858.CD010346.pub2

10. Andrea Cortés-Ladino C, Augusto Arias-Ortiz W, Porras-Ramírez A. Effectiveness of

Yoga and Acupuncture in Rheumatoid Arthritis: A Systematic Review and Meta-

Analysis. *Evid Based Complement Alternat Med*. 2023;2023:9098442.

doi:10.1155/2023/9098442

11. Chow SL, Bozkurt B, Baker WL, et al. Complementary and Alternative Medicines in the

Management of Heart Failure: A Scientific Statement From the American Heart

Association. *Circulation*. 2023;147(2):e4-e30. doi:10.1161/CIR.0000000000001110

12. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and

Chronic Low Back Pain: A Clinical Practice Guideline From the American College of

Physicians. *Ann Intern Med*. 2017;166(7):514-530. doi:10.7326/M16-2367

13. Vitacca M, Clini E, Bianchi L, Ambrosino N. Acute effects of deep diaphragmatic

breathing in COPD patients with chronic respiratory insufficiency. *Eur Respir J*.

1998;11(2):408-415. doi:10.1183/09031936.98.11020408

14. Goyeche JR, Ago Y, Ikemi Y. Asthma: The yoga perspective. Part I. The somatopsychic

imbalance in asthma: towards a holistic therapy. *J Asthma Res*. 1980;17(3):111-121.

doi:10.3109/02770908009105671

15. Satish V, Rao RM, Manjunath NK, et al. Yoga versus physical exercise for cardio-

respiratory fitness in adolescent school children: a randomized controlled trial. *Int J*

Adolesc Med Health. 2018;32(3). doi:10.1515/ijamh-2017-0154

16. Shaw I, Shaw BS, Brown GA. Role of diaphragmatic breathing and aerobic exercise in

improving pulmonary function and maximal oxygen consumption in asthmatics.

Science & Sports. 2010;25(3):139-145. doi:10.1016/j.scispo.2009.10.003

17. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An

Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*.

2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST

18. Park J, McCaffrey R, Newman D, Liehr P, Ouslander JG. A Pilot Randomized Controlled

Trial of the Effects of Chair Yoga on Pain and Physical Function Among Community-

Dwelling Older Adults With Lower Extremity Osteoarthritis. *J American Geriatrics*

Society. 2017;65(3):592-597. doi:10.1111/jgs.14717

19. Swigris JJ, Andrae DA, Churney T, et al. Development and Initial Validation Analyses of

the Living with Idiopathic Pulmonary Fibrosis Questionnaire. *Am J Respir Crit Care Med*.

2020;202(12):1689-1697. doi:10.1164/rccm.202002-0415OC

20. Scallan C, Strand L, Hayes J, et al. R-scale for pulmonary fibrosis: a simple, visual tool

for the assessment of health-related quality of life. *Eur Respir J*. 2022;59(1):2100917.

doi:10.1183/13993003.00917-2021

21. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief

Interstitial Lung Disease (K-BILD) health status questionnaire. *Thorax*. 2012;67(9):804-

810. doi:10.1136/thoraxjnl-2012-201581

22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*

Scand. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x

23. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness

scale. *Sleep*. 1991;14(6):540-545. doi:10.1093/sleep/14.6.540

24. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality

of life. *Health Policy*. 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9

25. Buysse DJ, Yu L, Moul DE, et al. Development and validation of patient-reported

outcome measures for sleep disturbance and sleep-related impairments. *Sleep*.

2010;33(6):781-792. doi:10.1093/sleep/33.6.781

26. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS™ sleep

disturbance and Sleep-Related Impairment item banks. *Behav Sleep Med*.

2011;10(1):6-24. doi:10.1080/15402002.2012.636266

27. Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and

meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF)

questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing

interstitial lung diseases. *BMJ Open Respir Res*. 2022;9(1):e001167.

doi:10.1136/bmjresp-2021-001167

28. Swigris J, Cutts K, Male N, Baldwin M, Rohr KB, Bushnell DM. The Living with Pulmonary

Fibrosis questionnaire in progressive fibrosing interstitial lung disease. *ERJ Open Res*.

2021;7(2):00145-02020. doi:10.1183/23120541.00145-2020

29. Nolan CM, Birring SS. PROMising developments in IPF patient-reported outcome

measures. *Eur Respir J*. 2022;59(1):2102312. doi:10.1183/13993003.02312-2021

30. Moor CC, Mostard RLM, Grutters JC, Bresser P, Wijsenbeek MS. The use of online visual

analogue scales in idiopathic pulmonary fibrosis. *Eur Respir J*. 2022;59(1):2101531.

doi:10.1183/13993003.01531-2021

31. Swigris JJ, Pryor JB, Aronson KI, Guess TA, Solomon JJ. Interstitial Lung Disease Patients'

Global Impressions of Symptoms, Severity Ratings, and Meaningfulness of Changes

Over Time. *Ann Am Thorac Soc*. Published online August 12, 2024.

doi:10.1513/AnnalsATS.202405-457OC

32. Khor YH, Johannson KA, Marcoux V, et al. Epidemiology and Prognostic Significance of

Cough in Fibrotic Interstitial Lung Disease. *Am J Respir Crit Care Med*. Published online

March 27, 2024:rccm.202311-2101OC. doi:10.1164/rccm.202311-2101OC

33. Wu Z, Smith DJF, Yazbeck L, et al. Cough Severity Visual Analog Scale Assesses Cough

Burden and Predicts Survival in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care*

Med. 2024;209(9):1165-1167. doi:10.1164/rccm.202311-2169LE

34. Anshu null, Singh N, Deka S, et al. The effect of yoga on pulmonary function in patients

with asthma: A meta-analysis. *Complement Ther Clin Pract*. 2023;50:101682.

doi:10.1016/j.ctcp.2022.101682

35. Cai Y, Ren X, Wang J, Ma B, Chen O. Effects of Breathing Exercises in Patients With

Chronic Obstructive Pulmonary Disease: A Network Meta-analysis. *Arch Phys Med*

Rehabil. 2024;105(3):558-570. doi:10.1016/j.apmr.2023.04.014

36. Brinsley J, Smout M, Davison K. Satisfaction with Online Versus In-Person Yoga During

COVID-19. *J Altern Complement Med*. 2021;27(10):893-896.

doi:10.1089/acm.2021.0062

37. Fell CD, Jessa I, Hatley S, Crawford L, Culos-Reed N. Yoga For Idiopathic Pulmonary

Fibrosis: A Pilot Study. In: *A42. NOVEL PHENOTYPES, OUTCOME MEASURES,*

TREATMENT STRATEGIES, AND COMORBID ILLNESS. American Thoracic Society;

2011:A1527-A1527. doi:10.1164/ajrccm-

conference.2011.183.1_MeetingAbstracts.A1527

38. Kreuter M, Wasmuth L, Kotzerke M, et al. Yoga in patients with fibrosing interstitial lung

diseases – a feasibility trial. In: *Idiopathic Interstitial Pneumonias*. European

Respiratory Society; 2020:773. doi:10.1183/13993003.congress-2020.773

39. Santana MJ, S-Parrilla J, Mirus J, Loadman M, Lien DC, Feeny D. An assessment of the

effects of Iyengar yoga practice on the health-related quality of life of patients with

chronic respiratory diseases: a pilot study. *Can Respir J*. 2013;20(2):e17-23.

doi:10.1155/2013/265406

40. Wang WL, Chen KH, Pan YC, Yang SN, Chan YY. The effect of yoga on sleep quality and

insomnia in women with sleep problems: a systematic review and meta-analysis. *BMC*

Psychiatry. 2020;20(1):195. doi:10.1186/s12888-020-02566-4

41. Hagmeyer L, Herkenrath SD, Treml M, Pietzke-Calcagnile A, Anduleit N, Randerath W.

Sleep-related breathing disorders in idiopathic pulmonary fibrosis are frequent and

may be associated with pulmonary vascular involvement. *Sleep Breath*.

2023;27(3):961-971. doi:10.1007/s11325-022-02686-z

42. Kolilekas L, Manali E, Vlami KA, et al. Sleep Oxygen Desaturation Predicts Survival in

Idiopathic Pulmonary Fibrosis. *Journal of Clinical Sleep Medicine*. 2013;09(06):593-

601. doi:10.5664/jcsm.2758

43. Troy LK, Young IH, Lau EMT, et al. Nocturnal hypoxaemia is associated with adverse

outcomes in interstitial lung disease. *Respirology*. 2019;24(10):996-1004.

doi:10.1111/resp.13549

44. van Manen MJG, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis.

Eur Respir Rev. 2016;25(141):278-286. doi:10.1183/16000617.0090-2015

45. Birring SS. Development of a symptom specific health status measure for patients with

chronic cough: Leicester Cough Questionnaire (LCQ). *Thorax*. 2003;58(4):339-343.

doi:10.1136/thorax.58.4.339

46. Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective cough frequency in Idiopathic

Pulmonary Fibrosis. *Cough*. 2010;6(1):4. doi:10.1186/1745-9974-6-4

47. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive

strategies for routine lung function tests. *Eur Respir J*. 2022;60(1):2101499.

doi:10.1183/13993003.01499-2021

FIGURE LEGENDS

1. Figure 1: CONSORT diagram.

2. Figure 2: Changes from baseline to week 12 for cough domain scores via L-IPF (panel

A), total scores via L-IPF (panel B), and cough domain scores via R-Scale-PF (panel

C), stratified by treatment arm. For all panels, each dot corresponds to a patient,

either in the control group (left subpanels) or the treatment group receiving the

modified yoga program (right subpanels). Patient observations from baseline to week

12 are joined by dashed lines, while the black solid line in each subpanel signifies the

change in average domain score from baseline to week 12 in the control (left) or

treatment (right) groups. Note that lower scores represent lesser

symptoms/impairment.

 TABLES

531 **Table 1.** Baseline characteristics of the study population.

	Control group (N=30)	Treatment group (N=30)	Overall (N=60)
Age (years)			
Mean (SD)	74.3 (7.41)	72.5 (8.97)	73.4 (8.21)
Body Mass Index (kg/m^2)			
Mean (SD)	26.5 (4.66)	27.6 (4.55)	27.1 (4.60)
Sex, n (%)			
Female	10 (33%)	9 (30%)	19 (32%)
Male	20 (67%)	21 (70%)	41 (68%)
Ethnicity, n (%)			
White	27 (90%)	27 (90%)	54 (90%)
Other	3 (10%)	3 (10%)	6 (10%)
Current/former smoker? n (%)			
No	19 (63%)	16 (53%)	35 (58%)
Yes	11 (37%)	14 (47%)	25 (42%)
Time since diagnosis (years)			
Median (Interquartile range)	3.6 (2.93)	3.0 (4.39)	3.2 (3.67)
[25th percentile – 75th percentile]	[2.31 – 5.24]	[1.92 – 6.30]	[2.21 – 5.88]
Surgical lung biopsy done? n (%)			
No	17 (57%)	19 (63%)	36 (60%)
Yes	13 (43%)	11 (37%)	24 (40%)
FVC (L)			
Mean (SD)	2.7 (0.77)	2.9 (0.86)	2.8 (0.82)
Median [25th percentile – 75th percentile]	2.7 [2.02 – 2.96]	3.1 [2.22 – 3.70]	2.8 [2.08 – 3.37]
FVC % predicted			
Mean (SD)	70.0 (21.84)	79.6 (20.28)	74.8 (21.44)
Median [25th percentile – 75th percentile]	70.5 [58.75 – 84.25]	77.5 [66.75 – 94.75]	73.0 [65.00 – 91.25]
DLCO (mmol/min/kPa)			
Mean (SD)	12.4 (3.41)	13.3 (4.42)	12.8 (3.93)
Missing	0 (0%)	1 (3.3%)	1 (1.7%)
DLCO % predicted value [*]			
Mean (SD)	52.5 (15.38)	56.0 (20.97)	54.0 (18.27)
Missing	0 (0%)	1 (3.3%)	1 (1.7%)
6MW distance (feet)			
Mean (SD)	1311 (405.7)	1269 (403.6)	1290 (401.7)
Missing	1 (3.3%)	1 (3.3%)	2 (3.3%)
Supplemental oxygen use, n (%) [†]			

	Control group (N=30)	Treatment group (N=30)	Overall (N=60)
Supplemental O2 not required	20 (67%)	18 (60%)	38 (63%)
Supplemental O2 required	10 (33%)	12 (40%)	22 (37%)
Obstructive sleep apnea reported, n (%)			
No	19 (63%)	13 (43%)	32 (53%)
Yes, without PAP therapy	4 (13%)	10 (33%)	14 (23%)
Yes, with PAP therapy	7 (23%)	7 (23%)	14 (23%)
Emphysema reported, n (%)			
No	29 (97%)	26 (87%)	55 (92%)
Yes	1 (3%)	4 (13%)	5 (8%)
Antifibrotics, n (%)			
No	3 (10%)	6 (20%)	9 (15%)
Yes	27 (90%)	24 (80%)	51 (85%)
Gastroesophageal reflux disease, n (%)			
No/Unknown	13 (43%)	15 (50%)	28 (47%)
Yes, confirmed by pH probe	14 (47%)	11 (37%)	25 (42%)
Yes, not confirmed by pH probe	3 (10%)	4 (13%)	7 (12%)
Pulmonary hypertension, n (%)			
No/Unknown	22 (73%)	16 (53%)	38 (63%)
Yes, confirmed by right heart catheterization	4 (13%)	7 (23%)	11 (18%)
Yes, not confirmed by right heart cath.	4 (13%)	7 (23%)	11 (18%)
Notes: [*] Percent predicted FVC and DLCO calculated using GLI reference equations [47]. [†] Supplemental oxygen use is a stratification factor.			

533 **Table 2. Changes from baseline to week 12 and adjusted treatment effect of modified yoga**

534 **program in primary outcomes for the study population.**

	Baseline*	Week 12*	Change† (Week 12 – Baseline)	Adjusted Treatment Effect of Yoga‡	
				Point estimate (95% CI)	p-value
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Cough)					
MYP	27.83 (25.69)	18.10 (21.23)	-9.31 (21.03)	-9.29 (-18.37, -0.20)	0.045
Control	24.83 (22.95)	25.00 (22.09)	0.17 (19.14)		
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Dyspnea)					
MYP	24.14 (21.81)	21.27 (20.02)	-1.61 (12.09)	-2.86 (-8.98, 3.27)	0.353
Control	21.27 (20.02)	22.86 (22.48)	0.99 (11.03)		
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Overall)					
MYP	30.84 (18.77)	23.37 (16.49)	-7.18 (13.57)	-7.11 (-13.15, -1.06)	0.022
Control	26.49 (19.60)	27.16 (19.92)	0.66 (10.70)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Cough)					
MYP	3.20 (2s.64)	2.07 (2.31)	-0.97 (2.29)	-1.18 (-2.27, -0.10)	0.034
Control	2.87 (2.21)	3.14 (2.56)	0.28 (2.05)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Shortness of Breath)					
MYP	4.13 (2.62)	4.00 (2.58)	0.00 (1.71)	-0.16 (-1.12, 0.80)	0.741
Control	3.27 (2.48)	3.66 (2.96)	0.38 (1.90)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Fatigue)					
MYP	4.43 (2.45)	4.31 (2.88)	0.00 (2.20)	0.09 (-1.05, 1.24)	0.869
Control	3.67 (2.66)	3.83 (3.08)	0.14 (2.08)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Mood)					
MYP	2.63 (2.61)	1.90 (2.54)	-0.79 (2.46)	-0.21 (-1.37, 0.96)	0.722
Control	1.63 (1.92)	1.48 (2.11)	-0.07 (2.09)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Wellbeing)					
MYP	3.03 (1.88)	3.21 (2.35)	0.07 (2.46)	-0.57 (-1.81, 0.67)	0.362
Control	2.80 (2.04)	3.48 (2.95)	0.72 (2.17)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Overall)					
MYP	17.43 (9.63)	15.48 (9.88)	-1.69 (8.65)	-2.27 (-6.68, 2.14)	0.306
Control	14.23 (8.84)	15.59 (10.93)	1.45 (7.60)		
King's Brief Interstitial Lung Disease (K-BILD) (Psychological)					
MYP	36.40 (10.52)	38.45 (9.10)	1.90 (8.51)	0.03 (-4.28, 4.35)	0.988
Control	40.20 (10.04)	40.17 (10.18)	-0.03 (9.95)		
King's Brief Interstitial Lung Disease (K-BILD) (Breathlessness and Activities)					
MYP	24.03 (8.72)	24.21 (7.89)	0.14 (4.76)	0.06 (-2.12, 2.25)	0.953
Control	25.57 (8.59)	25.63 (7.89)	0.07 (4.62)		
King's Brief Interstitial Lung Disease (K-BILD) (Chest Symptoms)					
MYP	11.27 (2.21)	11.93 (2.2)	0.62 (1.90)	0.24 (-0.61, 1.08)	0.578
Control	11.70 (2.31)	12.00 (2.12)	0.30 (1.58)		
King's Brief Interstitial Lung Disease (K-BILD) (Overall)					
Yoga	71.73 (17.79)	74.59 (17.27)	2.62 (11.73)	0.66 (-5.73, 7.04)	0.837
Control	77.57 (18.33)	77.80 (17.64)	0.23 (13.94)		
EuroQol-5D-5L (EQ-5D-5L) Visual Analogue Scale (VAS)					
MYP	70.53 (18.77)	70.76 (16.71)	0.90 (13.27)	2.60 (-3.56, 8.76)	0.400
Control	71.57 (21.88)	68.43 (21.66)	-3.13 (12.40)		
EuroQol-5D-5L (EQ-5D-5L) Index					

MYP	0.81 (0.11)	0.80 (0.16)	-0.01 (0.11)	0.00	0.853
Control	0.82 (0.10)	0.82 (0.12)	0.00 (0.07)	(-0.05, 0.04)	
Hospital Anxiety and Depression Scale (HADS) (Anxiety)					
MYP	4.80 (4.13)	3.90 (3.72)	-0.90 (2.87)	-0.10	0.859
Control	3.23 (2.49)	2.93 (2.66)	-0.17 (2.19)	(-1.28, 1.07)	
Hospital Anxiety and Depression Scale (HADS) (Depression)					
MYP	4.57 (3.82)	3.76 (3.52)	-0.90 (3.07)	-0.88	0.193
Control	4.17 (2.90)	4.28 (3.5)	0.17 (2.16)	(-2.21, 0.46)	
Hospital Anxiety and Depression Scale (HADS) (Overall)					
MYP	9.37 (7.45)	7.66 (6.68)	-1.79 (4.97)	-1.09	0.331
Control	7.40 (4.80)	7.17 (5.51)	-0.03 (3.59)	(-3.32, 1.14)	
Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance (SD)					
MYP	45.29 (9.52)	45.80 (8.73)	0.89 (8.60)	2.45	0.163
Control	48.62 (9.48)	46.29 (9.6)	-2.13 (5.76)	(-1.03, 5.93)	
Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep-Related Impairment (SRI)					
MYP	47.32 (8.78)	45.77 (8.08)	-1.10 (7.62)	-1.82	0.342
Control	44.63 (9.61)	45.92 (10.66)	1.58 (7.66)	(-5.63, 1.99)	
Epworth Sleepiness Scale (ESS)					
MYP	7.03 (3.94)	6.03 (4.40)	-0.90 (2.92)	-0.70	0.427
Control	4.63 (2.92)	4.90 (3.57)	0.38 (3.16)	(-2.44, 1.05)	

Notes:

[*] Week 12 is the end of the intervention period. Mean (standard deviation) values were computed for all patients with complete data at baseline and week 12.

[†] We perform an unadjusted comparison of the change (week 12 – baseline) of each of the primary outcomes between the two study arms (treatment and control).

[‡] A linear regression model was used treatment differences at week 12 for outcomes, adjusting for age, sex, BMI, supplementary oxygen usage, and the baseline value of the specific outcome measure under consideration. To handle missing data, multiple imputation was performed using the chained equations method. Pooled estimates, confidence intervals (CIs), and p-values were obtained using Rubin's rules (N=60) with * denoting statistically significant findings at level 0.05.

FIGURES

538   **Figure 1:** CONSORT diagram.

Figure 2: Changes from baseline to week 12 for cough domain scores via L-IPF (panel A),

total scores via L-IPF (panel B), and cough domain scores via R-Scale-PF (panel C), stratified

by treatment arm.

ONLINE DATA SUPPLEMENT

Title: <u>Y</u>oga <u>E</u>ffect on Quality-of-Life <u>S</u>tudy Among Patients with <u>I</u>diopathic <u>P</u>ulmonary

<u>F</u>ibrosis (YES-IPF)

Authors: Suha Kadura, Soumik Purkayastha, Josh Benditt, Amit Anand, Bridget Collins,

Miguele De Quadros, Mafara Hobson, MJ Biswas, Lawrence Ho, Cathie Spino, Ganesh

Raghu*

*__Corresponding Author:__ Ganesh Raghu, MD

University of Washington, Campus Box 356175, Seattle, WA 98195 USA

Email: graghu@uw.edu

1. Study title

Yoga effect on quality-of-life among patients with idiopathic pulmonary fibrosis (YES-IPF): A prospective, randomized control pilot trial by virtual means during the COVID-19 pandemic in Seattle, USA. ClinicalTrials.gov registration: NCT02848625 [link]

2. Background and Rationale

There has been ongoing debate regarding clinically meaningful endpoints for clinical trials involving patients with Idiopathic Pulmonary Fibrosis (IPF). Measurements of pulmonary function (forced vital capacity or FVC and diffusion capacity for Carbon Monoxide or DLCO) are often used, although it is often argued that assessing for change in quality of life measures and/or mortality would be more meaningful, patient centered outcomes [1].

There is only one study to date regarding the effect of yoga on the quality of life and physiologic measures of pulmonary function among patients with IPF. Fell et al presented an abstract in 2011 where patients with IPF participated in biweekly 75-minute yoga sessions for 4 weeks. At the end of 4 weeks, there were no significant changes in health-related quality of life (HRQoL) as measured by the SGRQ and SF-36 or in 6MWD. However, this study did demonstrate that a yoga program may be safe and feasible among patients with IPF. Yoga has been studied in other chronic lung diseases. Studies of the effect of yoga and associated breathing techniques on symptoms and physiologic parameters in patients with asthma have drawn variable conclusions [2,3]. Santana et al studied the effects of Iyenger yoga practice on patients with chronic lung disease awaiting lung transplant, 20% of whom had

IPF, and found that anxiety (by the Hospital Anxiety and Depression Score) and fatigue

(Chronic Respiratory Questionnaire) scores were improved after 12 weeks [4]. A meta-analysis

of 5 randomized controlled trials of COPD patients participating in yoga training

demonstrated some improvement in FEV1 and 6MWD, although quality of life measures

were not assessed [5]. This meta-analysis does, however, suggest that yoga programs can be

completed safely among patients with chronic lung disease. While participation in

pulmonary rehabilitation programs has been shown to improve dyspnea and quality of life in

patients with IPF, and is in fact recommended in evidence based guidelines, the effect of

complementary therapies requiring focused breathing techniques, such as yoga, on quality

of life, dyspnea and pulmonary function in this patient population has not yet been studied

[6–9].

Previous studies measuring quality of life in patients with IPF have used the St George's

Respiratory Questionnaire (SGRQ), the short form 36 health survey (SF-36), EuroQol

instrument, and A Tool to Assess Quality of life in IPF (ATAQ-IPF) [10]. In terms of differences

within the population of IPF patients, the initial study for ATAQ-IPF found that scores were

significantly different among patients who required supplemental O2 and those who did not,

with greater impairment among the former [11].

We propose to perform a pilot study of the effect of yoga on quality of life among patients

with IPF when compared to usual care. While Fell et al did not observe a significant change

in quality of life, their program was only 4 weeks long, and there was not a control group. We

will also measure any effect of yoga on pulmonary function measured by PFTs and 6MWD.

3. Objectives

Primary: Identify whether routine a modified yoga program/exercises 2 times per week x 12 weeks is associated with improved quality of life (measured by any of the 7 validated tools to assess HRQOL) compared to usual care among patients with IPF. Questionnaires that will be used include:

1. Living with Idiopathic Pulmonary Fibrosis questionnaire symptoms module (L-IPF symptoms).
2. Raghu scale for pulmonary fibrosis, or R-Scale-PF.
3. Hospital Anxiety and Depression (HAD) Scale.
4. King's Brief Interstitial Lung Disease questionnaire (K-BILD).
5. EuroQol-Five-Dimensional Five-Level questionnaire (EQ-5D-5L).
6. Epworth Sleepiness Scale (ESS).
7. Patient-Reported Outcomes Measurement Information System Sleep Disturbance and Sleep-Related Impairment (PROMIS SD and SRI).

Secondary: Determine whether IPF patients participating in MYP via Zoom classes x 12 weeks have

1. Improvement in FVC or less decline in FVC compared to control patients (usual care).
2. Improvement in 6-minute walk distance or less decline in 6-minute walk distance compared to control patients (usual care)

4. Trial Design: Randomized controlled trial (nonblinded)

Study population: Patients with IPF with diagnosis in accordance with 2018 ATS/ERS/JRS/ALAT criteria for diagnosis and management of IPF seen at the Center for ILD, UWMC.

Outcomes

1. Primary outcome: Change in QOL as measured by any of the 7 HRQOL questionnaires.
2. Secondary outcomes: % change in FVC over 12 weeks, % change in 6-minute walk distance (vs actual change in distance) over 12 weeks.

Exposure: Yoga 2 times per week, 1 hour per session, for 12 weeks through the Modified Yoga Program. The Modified Yoga Program consists of:

1. Pranayama (breathing exercises)
2. Asanas (seated yoga postures)
3. Dhyana (guided meditation)
4. Taught by Certified Yoga Teacher (CYT)
5. 2 x/week for 12 weeks

Participants received a secure link to a pre-recorded demo video to practice during their

free time.

Study population:

1. Include: Consecutive consented patients with IPF diagnosis seen in UWMC CILD

2. Exclude:

a. Patients with active malignancy

b. Comorbidities that would prohibitive: paralysis, musculoskeletal discomfort

100   or broken limbs, etc.

101   c. Patients being evaluate for lung transplant or receiving hospice care

102   d. Patients regularly participating in yoga and/or pulmonary rehabilitation

103   outside of the study at screening and during the study period

5. Methodology:

Sample size:

1. Acknowledging that this is the first study utilizing PROs as a primary outcome

measure and was undertaken as a pilot trial, the study sample size was chosen based

on feasibility considerations without formal power calculations.

2. Plan to randomize 60 eligible participants

3. Could consider power calculation based on KBILD MCID (MCID for KBILD in IPF is 3.9

points). Remaining PROs do not have clearly defined MCID for IPF.

Randomization method:

Eligible participants to be randomly allocated in a 1:1 ratio to yoga program or continuing

"usual day-to-day activities," with stratification by need to have supplemental oxygen prior

to study enrollment to account for disease severity.

1. Study statistician to prepare randomization schedule using computer-generated

permuted random blocks of size 4 for each stratum.

2. Sequence of allocation hidden from investigators to prevent selection bias.

Potential confounding factors: Sex, Age, Prior or current experience with yoga, Weight, and

Concomitant lung disease (mainly COPD or asthma)

Patient recruitment and consent:

1. Recruitment by nurse coordinators or study investigators.

2. Consent by study RNs

6. Statistical analysis plan:

Sample size/power calculation: The sample size for this pilot trial was determined based on

feasibility, as MCIDs for HRQoL instruments in IPF are not well established. Given the

exploratory nature of the study, hypothesis testing was conducted without p-value

adjustment for multiple endpoints. Point estimates with 95% confidence intervals (CIs) were

reported to compare treatment effects. The primary analysis set was the modified intention-

to-treat population, defined as all randomized participants with a week 12 visit.

Exploratory analysis and modeling: Descriptive statistics were presented for baseline, week

12, and change-from-baseline values in primary and secondary outcomes. For continuous

variables, means with standard deviations (SDs) or medians with interquartile ranges were

reported; categorical variables were summarized as frequencies and percentages.

Between-group comparisons for week 12 outcome scores were conducted using ANCOVA,

adjusting for baseline outcome scores, age, sex, BMI, and supplementary oxygen use. All

statistical analyses were performed in R, version 4.4.1.

Missing Data Handling: Missing data were addressed using multiple imputation with chained

equations (MICE) using the mice package version 3.17.0 [12]. One hundred imputations were

generated using Classification and Regression Trees (CART) as the imputation method. The

imputation model included sex, BMI, age, and treatment arm as predictors, selected to

ensure that all variables relevant to the analysis model were incorporated in the imputation

process. Each imputed dataset was analyzed separately using the pre-specified linear

regression model with post-treatment score as the outcome, adjusted for baseline

measurements, sex, BMI, age, oxygen levels, and treatment arm. Results from all 100

analyses were then pooled according to Rubin's rules to account for both within- and

between-imputation variability [13]. This approach provides unbiased parameter estimates

and correct standard errors under the missing at random (MAR) assumption. Stability of the

results was supported by the large number of imputations utilized, which exceeds standard

recommendations for complex analyses [14,15].

Sensitivity Analysis: Sensitivity analyses using complete cases were performed, applying the

same ANCOVA model but including only participants with complete data for all variables.

The robustness of the ANCOVA approach was assessed by checking the assumptions of

normality of residuals (Shapiro-Wilk test), homogeneity of variance (Bartlett's test), and

homogeneity of regression slopes (testing the interaction between baseline measurement

and treatment arm). While 6 of the 21 outcomes examined demonstrated slight deviations

from normality, our balanced design with adequate sample size (n=30 per group) ensures

the robustness of ANCOVA to mild violations of normality [16]. The other ANCOVA

assumptions were adequately met.

7. Description of questionnaires for PROs not included in main text:

K-BILD questionnaire: K-BILD contains 15 items, a seven-point Likert scale and three

domains (breathlessness and activities, psychological, and chest symptoms). The K-BILD

domain and total score ranges are 0–100; 100 represents best health status. The MCID for

the total K-BILD score is estimated to be 3.9 points in patients with ILD and IPF [17].

EQ-5D-5L: The EQ-5D-5L assesses five dimensions including mobility, self-care, usual

activities, pain/discomfort and anxiety/depression. Each domain has five possible

responses that are combined to form a sum utility score which is then converted into a

specific index value using a country-specific set (in our case USA in English). Those

completing the questionnaire also rate their overall health on a 20 cm VAS with a score of 0

representing "the worse health you can imagine" and 100 representing "the best health you

can imagine"[18]. The MCID estimate for the EQ-5D-5L in patients with fibrotic ILD, including

IPF, ranges from 0.0050 to 0.054 and from 0.078 to 0.095 for the anchor-based and

distribution-based methods, respectively [19].

HADS: The HADS is a self-reporting rating scale of 14 items on a 4-point Likert scale (range

0-3). It is designed to measure anxiety and depression (7 items for each domain). The total

score is the sum of the 14 items, and for each domain the score is sum of the respective 7

items (ranging from 0-21). A higher score indicates higher distress [20]. There is not an

established MCID for the HADS questionnaire in IPF patients.

PROMIS SD and SRI: Sleep disturbance and sleep-related impairment are measured using

PROMIS 8-item short forms. Both measures use a 5-point Likert scale. Each raw score is

converted to a standardized T-score using conversion tables published on the PROMIS

website (nihpromis.org), with higher scores indicating greater sleep/wake disturbances [21].

ESS: The ESS score (the sum of 8 item scores, 0-3) ranges from 0-24. The higher the score,

the higher that person's average sleep propensity in daily life or their "daytime sleepiness"

[22].

8. Journal format for treatment group study participants.

Name: ______________________________

My Yoga Journal

Date	Time & Length	Experiences in Meditation	Experiences in Activity	Additional Notes
	______ AM/PM ______ min.			
	______ AM/PM ______ min.			
	______ AM/PM ______ min.			
	______ AM/PM ______ min.			

"Yoga gives us a safe space and time to journey to the simplicity of breath and movement and connecting with ourselves." –Jill Conyers

9. Yoga session instructor script with pictures

INTRODUCTION : 5 minutes

Instructor: "Welcome to today's yoga session which should last about an hour. If you need to take a break at any time to use the restroom, cough or just catch your breath, please do so. The yoga practice we will do today is focused on relaxing and stretching and is not designed as vigorous exercise. Our practice will be to incorporate awareness of our breath with very gentle poses to expand our chest and relieve tightness in our muscles.

The session today is divided into 4 parts: 1. A few minutes of settling in, 2. A 25-minute session of gentle stretching postures, 3. A roughly 15-minute period of breathing exercises and 4. A 5-minute guided meditation to end the session.

Feel free to ask questions at any time, to stop the postures or exercises to take a break or just to sit quietly. This is your session.

First off, how are you doing today? Do you feel well enough to participate in the session today? If not, do not worry. You are welcome to stay with the group and just listen and do any of the practice that you feel able to. If you prefer to sign off the call, that is fine too. Again, these sessions are for you."

SETTLING IN: 5 minutes

Instructor: "Take time to get seated comfortably. It's better is you use a chair with a straight

back. If you can, sit forward in the chair in the upright position away from the backrest. If

not, it is okay to use the back for support.

It is now time to get in touch with your breath. You are welcome to close your eyes and take

off your shoes. Maybe try planting your feet hip width apart and align your ankles directly

underneath your knees. Extend your neck with a slight tuck of the chin and lengthen your

spine fully. Allow your arms to relax, and rest your palms face up or face down on your thighs.

Bring your shoulders back in line with the hips. Keep your chin level and draw it in slightly so

the head moves back in line with the shoulders.

We are trying to create a conscious stability from the base of your spine to the crown of your

head where you can feel at ease to breathe. Good posture promotes increased breath

awareness because there is suddenly much more room to take big, deep breaths.

Keeping your eyes closed, begin to bring your attention to your breath. Just notice where your

breath is right now in your body? Be curious about how you are breathing. How long is your

inhale? Your exhale? Notice what part of your body you are using most to breathe: your belly,

your chest, the back or front of your body, or is it just up top in the neck and shoulders? Let

the sounds of the environment fade into the background and let the sound of your breath

and the experience of the air moving in and out your lungs come to the foreground. Focus on

an open, expansive inhale, filling your lungs from the bottom to the top and a smooth, slow

exhale engaging your belly to press the air out of the lungs.

PAUSE to allow time for students to breathe

Allow all the thoughts of your day to fade, bring your attention if it wanders to the breath and

the body. Lengthen your inhale and slow down the exhale, breathing out through your mouth.

Maintain awareness of your posture, and continue to release excess tension with each

exhale, breathe the tension out. If the mind wanders, gently invite your attention back, and

follow the experience of the breath moving in and out of the body.

PAUSE again.

And now, gently open your eyes, and prepare for some gentle stretching. If you have any

discomfort during these movements, please feel free to ask your instructor to assist you in

modifying any of the exercises. If you feel the urge to cough during any of the exercises, feel

free to take a rest and do so.

SEATED EXERCISES: 25 minutes

1. SEATED "MOUNTAIN" POSE:

Instructor: We will start with the seated mountain pose. Sit with your spine and neck

straight and positioned with the shoulders over the hips. Place your hands, palm faced

down on your thighs. Take four or five deep breaths in this position.

PAUSE to allow the students to practice.

"Mountain" pose is very restful and is a good point to start each of the other poses from.

You can use it as an intermediate stop before you go on to your next pose. It is a very

"centering" position for you.

2. SHOULDER CIRCLES:

With your hands at your sides, gently move your shoulders in a circle. Start by making

a forward circular motion for 5 repetitions. (INSTRUCTOR DEMONSTRATE)

Then roll the shoulders in the opposite direction for 5 repetitions. (INSTRUCTOR

DEMONSTRATE).

Move into your mountain pose for one or two breaths and relax.

3. SUPPORTED NECK STRETCH:

Instructor: Next, we will very gently stretch the neck. Place your right hand on the crown of

your head with the fingers over the temple. If your shoulder does not feel comfortable in that

position, you may leave the arm at your side and stretch the neck gently using the weight of

your head. Straighten your left arm down slightly away from your side, keeping the elbow and

the wrist extended while stretching out the fingers fully. Gently pull your head to the right

and hold for 10 seconds.

PAUSE

Drop your hands to your sides. Repeat the same stretch but this time on the opposite side

with your left hand on the crown of your head and your right arm extended to the side. Gently

pull your head to the left, while straightening out your right arm slightly away from your side.

Keep the elbow and the wrist extended for 10 seconds. Return to mountain pose for two or

three relaxing breaths.

4. SEATED "CAT/COW" POSE:

In "cow/cat" pose, move your hands, palms face-down to your knees. Inhale, gently lifting

your gaze upward and allowing your spine to arch forward imitating the spine of a cow.

Exhale, slowly dropping your chin to your chest, allow your spine to gently round backwards

like a cat. This should be a gentle motion, not forced or uncomfortable. It is helpful to

synchronize the breath with the movement of the spine. Breath in, gentle arching of the spine

while looking up, breath out, gently rounding the spine. Performing 5 to 7 repetitions of

arching and rounding, coupled with the breath is ideal.

PAUSE to allow the students to finish.

Bring yourself back to mountain pose and relax.

5. SEATED SIDE BENDS:

Instructor: Next we will do seated side bends. Starting from mountain pose, raise your left

arm slowly (with your palm facing the ceiling) above your head straight up. Very gently, begin

bending laterally to the right. Do not force this. There should be no pinching or discomfort

in the spine or ribs. Breathe in and out for 4 or 5 breaths in this position. PAUSE.

You may notice that as you exhale you are able to bend slightly deeper. Gently return to the

upright position and bring your left arm down. Now, raise your RIGHT arm up and bend gently

to the left side. Again, do not force this bend. Take 4 or 5 breaths in this position.

PAUSE.

Gently return to the upright position and drop your right arm down.

6. SEATED SPINAL TWIST

Instructor: " Our next posture is the seated spinal twist. Starting again from the relaxed

mountain pose with your spine straight and long, gently and slowly twist to the left placing

your left forearm on the back of your chair. Place your right hand on your left thigh or the left

edge of the seat and relax. To deepen the stretch, exhale and GENTLY pull with your right

hand. Do not force this. There should be no pain in the spine. If there is any discomfort,

back out of this position and tell your instructor. If you are comfortable take 4 or 5 breaths in

this position and then return to mountain pose. Begin the twist on the right side by gently

twisting to the right and placing your right forearm on the back of your chair. Place your left

hand on your right thigh or the edge of the chair and, if you are comfortable, gently deepen

the twist by pulling with your left hand. Take 4 or 5 breaths in this position. Return to

mountain pose when you are finished. "

Breathing Exercises: 15 minutes

Instructor: How do you feel after our gentle yoga poses? If you need to take a drink, relax or

change positions, go ahead. In our next exercises, we will be focused on our breath.

1. Counted breaths:

Instructor: In this exercise, we will use a metronome that I will set up for us and set a relaxed

pace to help you begin to focus on the length of your inhales and exhales. Sitting in a relaxed

position with your spine straight (seated mountain pose works great) we will use the

metronome to count 3 counts during inhalation and 3 counts during exhalation. Later as we

become more experienced, we gradually make the exhalation longer than inhalation but

now we will focus on making inhalation and exhalation equal.   It is best if you can breathe

in and out through your nostrils but if you cannot, through the mouth is fine or in through the

nose and out through the mouth.

Instructor: continue this for about one minute and then give the group a break. Any

questions?

2. Counted "victory breaths" (ujjayi)

Instructor: In this breathing exercise we will be performing the same exercise as we just did

but we will be adding something called ujjayi or victory breathing. Victory breathing is

performed by very slightly constricting the throat to make a soft sound like waves on the

beach. A way to think of the sound is if you are trying to clean a pair of sunglasses by fogging

them up before you clean them. DEMONSTRATE TO PARTICIPANTS (i.e. Darth Vader breath

or AAAH and HAAA). Take a breath in and exhale like you are trying to fog the glasses and

listen to the sound (this is the sound of the victory breath).Then with the same slight

constriction of the throat, take a breath in. Again, if possible, you should breath in and out

through your nose. Practice taking several breaths in this way and we will then use the

metronome and once again count three beats to inhale and three beats to exhale.

Instructor: Have them do this for 45-60 seconds or about 10 breaths. How did that feel? Any

questions?

3. Cooling Breath:

Instructor: For this breath technique, which involves drawing air across your tongue and into

your mouth, having a "cooling or calming" effect on the nervous system, can be done one of

two ways. You can curl the sides of your tongue inward, like you are sucking air through a

straw, or if you can't do that, you can sit your tongue right behind your front teeth and draw

air in around your tongue. DEMONSTRATE.

Instructor: Have them practice and once questions are answered have them perform the

cooling breath for about 30 seconds.

Brahmari (Buzzing Bee) Breath:

Place your thumbs in your ears and your tips of the fingers over your closed eyelids. Take a

deep breath in. Then, while **exhaling, generate a LOUD humming noise so as to feel this**

vibration resonate through the face and the scalp. DEMONSTRATE. Make sure you exhale

fully allowing the subsequent inhale to be even deeper. Do this for 5 to 7 breaths at your own

pace, with the tone that seems most comfortable. Then release the hands onto the thighs

and let the breathing settle. Feel the warmth and the calm envelop you.

CLOSING GUIDED MEDITATION: 5 minutes

Instructor: Come into a position that is comfortable for you. Let the legs feel heavy. Soften

your jaw. Bring your attention once again to your breath. You can breathe slowly keeping

inhalation and exhalation slow and in a pattern and rate that feels relaxed and comfortable.

Let your whole body melt into the chair, letting go of stiffness or tension in the spine. If your

mind becomes distracted by thought, return your awareness to your breath, this inhalation,

and this exhalation, being mindful to keep your attention focused in the present moment

without trying to change it, and letting everything else be as it is.

Continue to allow your body to relax. Breathe in, breathe out. Take a big cleansing breath

and breathe the tension out of your body. You can even make an audible ahhh sound on your

next exhale. Let's try this together, inhale deeply and on your next exhale, open the

mouth...ahhhh. One more. Feel the relaxation beginning at the bottom of your feet. Relax

your toes.

Let the relaxation spread over your feet and up your ankles, spreading up your calves, and

into your knees, softening the backs of your knees and releasing any tension or stiffness in

your knees. Feel the relaxation spreading up your legs, feel the tension melt away in your

hips and lower back. Release any tension in your lower back. Allow the relaxation to spread

upward to your upper back and shoulders. Let go of tension in the shoulders. Feel the

relaxation spread up the front of your body starting with your belly, let it be soft, rising and

falling with each breath. Let your chest relax, slide your shoulder back, giving you a little

more room to breathe easy. Now feel your upper arms relax and let the feeling spread into

your elbows and forearms. Let go of tension or stiffness in the hands, relax the palm of your

hand, the back of your hand, relax your fingers. Your hands, your arms, feel heavy and warm.

Feel your body unwind even further as you expand your chest open on each inhale and you

feel your collar bones widen and relax down. Allow your shoulder blades to ease back

slightly and continue to breathe deeply. Deep inhale, slow exhale. Notice your shoulders

and your neck, let go of the tension in your neck. Feel the relaxation continue to your chin,

let your jaw slacken, release your tongue from the roof of your mouth. Let your eyelids be

heavy and relaxed, letting your eyeballs drift back. Notice your eyebrows unfurrowing and

relaxing down, let your forehead become smooth and cool; the back of your head relaxes.

Let the feeling of relaxation spread to the crown of your head; from the tips of your toes to

the top of your head, your entire body is now calm and relaxed. Continue to feel the

relaxation and sense of calm flow throughout your body from your head to your feet and

back. Notice all of the muscles in your body relaxing completely. Feel your spine lengthen

and melt into the chair, your limbs are heavy and warm. Continue to breathe smoothly and

slowly as you mentally scan your body, looking for any remaining tension. If you notice any

tension, focus on that area and direct the relaxation to flow into that area, carrying away any

residual tension.

Relax and return to your Mountain pose. Do you have an questions or thoughts you would

like to bring up ? How does everyone feel now that we have completed our session for

today ?

REFERENCES

1. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic Pulmonary Fibrosis: Clinically
Meaningful Primary Endpoints in Phase 3 Clinical Trials. *Am J Respir Crit Care Med*.
2012;185(10):1044-1048. doi:10.1164/rccm.201201-0006PP

2. Cramer H, Posadzki P, Dobos G, Langhorst J. Yoga for asthma: a systematic review and
meta-analysis. *Ann Allergy Asthma Immunol*. 2014;112(6):503-510.e5.
doi:10.1016/j.anai.2014.03.014

3. Cooper S, Oborne J, Newton S, et al. Effect of two breathing exercises (Buteyko and
pranayama) in asthma: a randomised controlled trial. *Thorax*. 2003;58(8):674-679.
doi:10.1136/thorax.58.8.674

4. Santana MJ, S-Parrilla J, Mirus J, Loadman M, Lien DC, Feeny D. An assessment of the
effects of Iyengar yoga practice on the health-related quality of life of patients with
chronic respiratory diseases: a pilot study. *Can Respir J*. 2013;20(2):e17-23.
doi:10.1155/2013/265406

5. Liu XC, Pan L, Hu Q, Dong WP, Yan JH, Dong L. Effects of yoga training in patients with
chronic obstructive pulmonary disease: a systematic review and meta-analysis. *J Thorac*
Dis. 2014;6(6):795-802. doi:10.3978/j.issn.2072-1439.2014.06.05

6. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients
with idiopathic pulmonary fibrosis. *Respirology*. 2008;13(3):394-399.
doi:10.1111/j.1440-1843.2007.01205.x

7. Vainshelboim B, Oliveira J, Yehoshua L, et al. Exercise training-based pulmonary
rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis.
Respiration. 2014;88(5):378-388. doi:10.1159/000367899

8. Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary
rehabilitation in patients with interstitial lung disease. *Eur Respir J*. 2013;42(2):444-453.
doi:10.1183/09031936.00081512

9. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic
pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J*
Respir Crit Care Med. 2011;183(6):788-824. doi:10.1164/rccm.2009-040GL

10.   Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M,
et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. *N Engl J*
Med. 2010;363(7):620-628. doi:10.1056/NEJMoa1002110

11.   Swigris JJ, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS.
Development of the ATAQ-IPF: a tool to assess quality of life in IPF. *Health Qual Life*
Outcomes. 2010;8:77. doi:10.1186/1477-7525-8-77

12.   Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained
Equations in R. *Journal of Statistical Software*. 2011;45:1-67. doi:10.18637/jss.v045.i03

13.   Raghunathan T. *Missing Data Analysis in Practice*. 0 ed. Chapman and Hall/CRC;
2015. doi:10.1201/b19428

14.   Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed?
Some practical clarifications of multiple imputation theory. *Prev Sci*. 2007;8(3):206-213.
doi:10.1007/s11121-007-0070-9

15.   Bodner TE. What Improves with Increased Missing Data Imputations? *Structural*
Equation Modeling: A Multidisciplinary Journal. 2008;15(4):651-675.
doi:10.1080/10705510802339072

16.   Glass GV, Peckham PD, Sanders JR. Consequences of Failure to Meet Assumptions
Underlying the Fixed Effects Analyses of Variance and Covariance. *Review of*
Educational Research. 1972;42(3):237-288. doi:10.2307/1169991

17.   Nolan CM, Birring SS, Maddocks M, et al. King's Brief Interstitial Lung Disease
questionnaire: responsiveness and minimum clinically important difference. *Eur Respir*
J. 2019;54(3):1900281. doi:10.1183/13993003.00281-2019

18.   EuroQol Group. EuroQol--a new facility for the measurement of health-related
quality of life. *Health Policy*. 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9

19.   Tsai APY, Hur SA, Wong A, et al. Minimum important difference of the EQ-5D-5L and
EQ-VAS in fibrotic interstitial lung disease. *Thorax*. 2021;76(1):37-43.
doi:10.1136/thoraxjnl-2020-214944

20.   Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*
Scand. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x

21.   Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS™
sleep disturbance and Sleep-Related Impairment item banks. *Behav Sleep Med*.
2011;10(1):6-24. doi:10.1080/15402002.2012.636266

22.   Johns MW. A new method for measuring daytime sleepiness: the Epworth
sleepiness scale. *Sleep*. 1991;14(6):540-545. doi:10.1093/sleep/14.6.540

FIGURE LEGENDS

1. **Figure E1:** Study Protocol.

2. **Figure E2:** Central themes contributing to improved sense of well-being among yoga participants.

3. **Figure E3:** Cough domain score via the Living with Idiopathic Pulmonary Fibrosis scale (L-IPF) (panel A), total score via the Living with Idiopathic Pulmonary Fibrosis scale (L-IPF) (panel B), and cough domain score via the Raghu scale for pulmonary fibrosis (R-Scale-PF) (panel C) from baseline to week 12. Each dot corresponds to a patient, either in the control group (left panel) or the treatment group following the modified yoga program (right panel). Patient observations are overlaid on top of violin plots and displayed twice within each panel: once at baseline and again at week 12. Lower scores represent lesser symptoms/impairment.

TABLES

507   **Table E1:** Description of yoga poses.

Pose name	Description	Frequency	Duration
Asanas (postures)			
Parvatasana (seated mountain pose)	Straight back, lengthen up spine, relax shoulders down, neutral chest/diaphragm, deep breaths	Starting point prior to subsequent poses	2 min
Chair seated shoulder circles	Roll shoulders in a circular motion (both directions, 5 repetitions)	1 round	2 min
Seated neck stretches	Gently pull head to each side and hold	1 round	2 min
Marjayasana-bitilasana (seated cat cow pose)	Inhale and arch spine forward, exhale and round spine backwards	5-7 repetitions	4 min
Parsva Sukhasana (seated side bend pose)	Raise arm and bend laterally to each side	1 round	2 min
Ardha Matsyendrasana (seated spinal twist)	Twist to each side, rotating the spine, opening shoulders and chest	1 round	3 min
Pranayama (breathing exercises)			
Counted breaths	Through nostrils, 3 counts inhalation, 3 counts exhalation using metronome to set pace	1 round	1 min
Ujjayi (counted "victory breaths"	As above, adding throat constriction	1 round	1 min
Cooling breath	Curl sides of tongue inward, inhale, exhale	1 round	30 sec
Brahmari (buzzing bee breath)	Place thumbs in ears and fingers over closed eyelids, inhale, exhale with loud humming noise	1 round	1 min
Dhyana (meditation)			
Guided mediation	N/A	1 round	5 min

509 **Table E2:** Changes from baseline to week 12 and adjusted treatment effect of modified

510 yoga program on secondary endpoints for the study population.

	Baseline [*]	Week 12 [*]	Change [†] (Week 12 – Baseline)	Adjusted Treatment Effect of Yoga [‡]	
				Point estimate (95% CI)	p-value
Absolute Forced Vital Capacity (FVC) (L)					
MYP	2.95 (0.86)	2.82 (0.86)	-0.11 (0.23)	0.02 (-0.19, 0.23)	0.88
Control	2.67 (0.77)	2.54 (1.02)	-0.13 (0.54)		
Percent Predicted Forced Vital Capacity (FVC) (%)					
MYP	79.57 (20.28)	77.07 (21.97)	-2.55 (6.09)	0.25 (-6.99, 7.49)	0.94
Control	70.03 (21.84)	70.63 (24.80)	0.60 (19.06)		
Absolute Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) (ml/min/kPa)					
MYP	13.27 (4.42)	12.08 (3.93)	-1.18 (1.88)	-0.41 (-1.66, 0.84)	0.51
Control	12.38 (3.41)	11.50 (4.60)	-0.85 (2.66)		
Percent Predicted Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) (%)					
MYP	56.03 (20.97)	52.48 (20.28)	-3.11 (12.03)	-0.73 (-7.10, 5.63)	0.82
Control	52.47 (15.38)	49.79 (19.98)	-2.28 (11.25)		
6-minute walking test (6MWT) (feet)					
MYP	1268.79 (403.62)	1195.37 (383.21)	-69.92 (143.71)	83.49 (-30.09, 197.08)	0.15
Control	1311.07 (405.74)	1166.76 (526.65)	-146.07 (279.52)		

Notes:
[*] Week 12 is the end of the intervention period. Mean (standard deviation) values were computed for all patients with complete data at baseline and week 12.
[†] We perform an unadjusted comparison of the change (week 12 – baseline) of each of the primary outcomes between the two study arms (treatment and control).
[‡] A linear regression model was used treatment differences at week 12 for outcomes, adjusting for age, sex, BMI, supplementary oxygen usage, and the baseline value of the specific outcome measure under consideration. To handle missing data, multiple imputation was performed using the chained equations method. Pooled estimates, confidence intervals (CIs), and p-values were obtained using Rubin's rules (N=60).

Table E3: Complete case analysis for changes from baseline to week 12 and adjusted treatment effect of modified yoga program on primary endpoints for the study population.

| | Baseline* | Week 12* | Change† (Week 12 – Baseline) | Adjusted Treatment Effect of Yoga‡ | |
				Point estimate (95% CI)	p-value
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Cough)					
MYP	27.83 (25.69)	18.10 (21.23)	-9.31 (21.03)	-8.59 (-17.50, 0.33)	0.065
Control	24.83 (22.95)	25.00 (22.09)	0.17 (19.14)		
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Dyspnea)					
MYP	24.14 (21.81)	21.27 (20.02)	-1.61 (12.09)	-2.93 (-8.77, 2.90)	0.329
Control	21.27 (20.02)	22.86 (22.48)	0.99 (11.03)		
Living with Idiopathic Pulmonary Fibrosis (L-IPF) (Overall)					
MYP	30.84 (18.77)	23.37 (16.49)	-7.18 (13.57)	-7.14 (-13.06, -1.23)	0.022
Control	26.49 (19.60)	27.16 (19.92)	0.66 (10.70)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Cough)					
MYP	3.20 (2s.64)	2.07 (2.31)	-0.97 (2.29)	-1.19 (-2.24, -0.14)	0.031
Control	2.87 (2.21)	3.14 (2.56)	0.28 (2.05)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Shortness of Breath)					
MYP	4.13 (2.62)	4.00 (2.58)	0.00 (1.71)	-0.08 (-1.01, 0.84)	0.859
Control	3.27 (2.48)	3.66 (2.96)	0.38 (1.90)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Fatigue)					
MYP	4.43 (2.45)	4.31 (2.88)	0.00 (2.20)	0.09 (-1.05, 1.22)	0.884
Control	3.67 (2.66)	3.83 (3.08)	0.14 (2.08)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Mood)					
MYP	2.63 (2.61)	1.90 (2.54)	-0.79 (2.46)	-0.18 (-1.30, 0.95)	0.757
Control	1.63 (1.92)	1.48 (2.11)	-0.07 (2.09)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Wellbeing)					
MYP	3.03 (1.88)	3.21 (2.35)	0.07 (2.46)	-0.54 (-1.79, 0.70)	0.395
Control	2.80 (2.04)	3.48 (2.95)	0.72 (2.17)		
Raghu Scale for Pulmonary Fibrosis (R-scale-PF) (Overall)					
MYP	17.43 (9.63)	15.48 (9.88)	-1.69 (8.65)	-2.12	0.336

				(-6.39, 2.16)	
Control	14.23 (8.84)	15.59 (10.93)	1.45 (7.60)		
King's Brief Interstitial Lung Disease (K-BILD) (Psychological)					
MYP	36.40 (10.52)	38.45 (9.10)	1.90 (8.51)	0.33 (-3.85, 4.50)	0.879
Control	40.20 (10.04)	40.17 (10.18)	-0.03 (9.95)		
King's Brief Interstitial Lung Disease (K-BILD) (Breathlessness and Activities)					
MYP	24.03 (8.72)	24.21 (7.89)	0.14 (4.76)	0.05 (-2.09, 2.20)	0.960
Control	25.57 (8.59)	25.63 (7.89)	0.07 (4.62)		
King's Brief Interstitial Lung Disease (K-BILD) (Chest Symptoms)					
MYP	11.27 (2.21)	11.93 (2.2)	0.62 (1.90)	0.27 (-0.54, 1.08)	0.514
Control	11.70 (2.31)	12.00 (2.12)	0.30 (1.58)		
King's Brief Interstitial Lung Disease (K-BILD) (Overall)					
Yoga	71.73 (17.79)	74.59 (17.27)	2.62 (11.73)	1.09 (-5.11, 7.28)	0.733
Control	77.57 (18.33)	77.80 (17.64)	0.23 (13.94)		
EuroQol-5D-5L (EQ-5D-5L) Visual Analogue Scale (VAS)					
MYP	70.53 (18.77)	70.76 (16.71)	0.90 (13.27)	2.62 (-3.44, 8.68)	0.401
Control	71.57 (21.88)	68.43 (21.66)	-3.13 (12.40)		
EuroQol-5D-5L (EQ-5D-5L) Index					
MYP	0.81 (0.11)	0.80 (0.16)	-0.01 (0.11)	-0.00 (-0.05, 0.04)	0.837
Control	0.82 (0.10)	0.82 (0.12)	0.00 (0.07)		
Hospital Anxiety and Depression Scale (HADS) (Anxiety)					
MYP	4.80 (4.13)	3.90 (3.72)	-0.90 (2.87)	-0.10 (-1.22, 1.02)	0.860
Control	3.23 (2.49)	2.93 (2.66)	-0.17 (2.19)		
Hospital Anxiety and Depression Scale (HADS) (Depression)					
MYP	4.57 (3.82)	3.76 (3.52)	-0.90 (3.07)	-0.84 (-2.17, 0.48)	0.218
Control	4.17 (2.90)	4.28 (3.5)	0.17 (2.16)		
Hospital Anxiety and Depression Scale (HADS) (Overall)					
MYP	9.37 (7.45)	7.66 (6.68)	-1.79 (4.97)	-1.04 (-3.16, 1.09)	0.345
Control	7.40 (4.80)	7.17 (5.51)	-0.03 (3.59)		
Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance (SD)					
MYP	45.29 (9.52)	45.80 (8.73)	0.89 (8.60)	2.35 (-1.10, 5.79)	0.188
Control	48.62 (9.48)	46.29 (9.6)	-2.13 (5.76)		
Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep-Related Impairment (SRI)					
MYP	47.32 (8.78)	45.77 (8.08)	-1.10 (7.62)	-1.77 (-5.50, 1.95)	0.356
Control	44.63 (9.61)	45.92 (10.66)	1.58 (7.66)		

Epworth Sleepiness Scale (ESS)					
MYP	7.03 (3.94)	6.03 (4.40)	-0.90 (2.92)	-0.79 (-2.49, 0.91)	0.367
Control	4.63 (2.92)	4.90 (3.57)	0.38 (3.16)		

Notes:

[*] Week 12 is the end of the intervention period. Mean (standard deviation) values were computed for all patients with complete data at baseline and week 12.

[†] We perform an unadjusted comparison of the change (week 12 – baseline) of each of the primary outcomes between the two study arms (treatment and control).

[‡] A linear regression model was used treatment differences at week 12 for outcomes, adjusting for age, sex, BMI, supplementary oxygen usage, and the baseline value of the specific outcome measure under consideration. Complete case analysis results presented here.

517   **Figure E1:** Study protocol.

519   **Figure E2:** Central themes contributing to improved sense of well-being among yoga

520   participants.

Figure E3. Cough domain score via the Living with Idiopathic Pulmonary Fibrosis scale (L-IPF) (panel A), total score via the Living with Idiopathic Pulmonary Fibrosis scale (L-IPF) (panel B), and cough domain score via the Raghu scale for pulmonary fibrosis (R-Scale-PF) (panel C) from baseline to week 12.